Edwards Lifesciences Corporation
EWHealthcareNASDAQMedical Devices · Last scanned Jun 2, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Edwards Lifesciences Corporation focuses on Medical Devices services and products. Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. At a $50.47B market cap, Edwards Lifesciences Corporation ranks as a large-cap company within healthcare. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
Market Cap
$50.47B
Beta
0.87
P/E (TTM)
47.38
P/E (Fwd)
26.03
EPS (TTM)
$1.85
EPS (Fwd)
$3.37
ROE
10.5%
ROA
8.3%
Cash
$3.67B
Total Debt
$702.9M
Free CF
$902.1M
52W Change
12.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $3.67B in cash comfortably exceeding the $702.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $902.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 10.5%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $4.46B (2022) to $6.07B (2025), reflecting a 36% increase over the period.
With cash comfortably exceeding debt, EW has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Edwards Lifesciences Corporation's trajectory.